Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine

The Coronavirus Disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Related Coronavirus 2 (SARS-CoV-2) is a global health emergency. As only very limited therapeutic options are clinically available, there is an urgent need for the rapid development of safe, effective, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Schloer, Sebastian, Brunotte, Linda, Goretzko, Jonas, Mecate-Zambrano, Angeles, Korthals, Nadia, Gerke, Volker, Ludwig, Stephan, Rescher, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594754/
https://www.ncbi.nlm.nih.gov/pubmed/32975484
http://dx.doi.org/10.1080/22221751.2020.1829082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594754/
https://www.ncbi.nlm.nih.gov/pubmed/32975484
http://dx.doi.org/10.1080/22221751.2020.1829082

Ejemplares similares